PPM1D — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL8816848	0.41	13/20
SCHEMBL7345040	0.41	7/20
SCHEMBL6117765	0.57	6/20
SCHEMBL15320811	0.46	4/20
SCHEMBL12143691	0.77	3/20
SCHEMBL12143696	0.77	3/20
SCHEMBL15827347	0.77	3/20
SCHEMBL9005566	0.64	3/20
SCHEMBL9005670	0.64	3/20
SCHEMBL23022858	0.60	3/20
SCHEMBL21088517	0.57	3/20
SCHEMBL2197741	0.53	3/20
SCHEMBL2361733	0.52	3/20
SCHEMBL3853181	0.51	3/20
SCHEMBL25793900	0.51	3/20
SCHEMBL20844588	0.50	3/20
SCHEMBL23022833	0.50	3/20
SCHEMBL26436295	0.49	3/20
SCHEMBL20400984	0.48	3/20
SCHEMBL11619594	0.47	3/20

Clinical trials — most relevant to PPM1D by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome	PHASE3	COMPLETED
Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome	PHASE1/PHASE2	COMPLETED
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer	PHASE2	COMPLETED
Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes	PHASE2	COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Leniolisib for Immune Dysregulation in PIDs	PHASE2	ACTIVE_NOT_RECRUITING
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer	PHASE1/PHASE2	RECRUITING
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)	PHASE1/PHASE2	WITHDRAWN
Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma	PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma	PHASE1/PHASE2	COMPLETED
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer	PHASE1/PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma	PHASE1	COMPLETED
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors	PHASE1	WITHDRAWN
Palliative Thoracic Radiotherapy Plus BKM120	PHASE1	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies	nan	RECRUITING
NGS in Gallbladder Cancer and Response to Treatment	nan	RECRUITING
Clinical Genetics Branch Eligibility Screening Survey	nan	NOT_YET_RECRUITING
Quantification of GADD34 Expression in RA	nan	COMPLETED
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia	nan	UNKNOWN
Immune Signature of Palmoplantar Pustulosis	nan	COMPLETED
Study of Metabolic Modifications in Children With Noonan Syndrome	nan	COMPLETED
Exome Sequencing for Atypical Femoral Fractures	nan	COMPLETED
Study of Proteus Syndrome and Related Congenital Disorders	nan	RECRUITING
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors	nan	UNKNOWN
Use of miRNAs in Growth Hormone Deficiency (GHD)	nan	UNKNOWN
The Chinese Mutation Hotspot of ENaC Causing Liddle's Syndrome and the Association of ENaC Variations and Hypertension	nan	SUSPENDED

Related proteins — ESM-2 sequence neighbours (a PPM1D binder may also engage these)

Protein	Name	Similarity
Q9QZ67	—	1.000	Q9QZ67 →
Q9LZ86	—	0.986	Q9LZ86 →
Q9SR24	—	0.984	Q9SR24 →
O82302	—	0.984	O82302 →
Q8RWN7	—	0.983	Q8RWN7 →
Q9ZV25	—	0.982	Q9ZV25 →
Q7XTC7	—	0.982	Q7XTC7 →
Q9M1V8	—	0.981	Q9M1V8 →
Q9CAV6	—	0.980	Q9CAV6 →
Q7XVF9	—	0.980	Q7XVF9 →
Q5TKR9	—	0.980	Q5TKR9 →
Q08AX9	—	0.980	Q08AX9 →
Q68UT7	—	0.980	Q68UT7 →
Q6Z9D2	—	0.980	Q6Z9D2 →
Q84T94	—	0.980	Q84T94 →
Q8BVT6	—	0.979	Q8BVT6 →
Q6NQ79	—	0.979	Q6NQ79 →
Q6ZKL8	—	0.979	Q6ZKL8 →
KCNQ5	Potassium voltage-gated channel subfamily KQT member 5	0.979	landscape →
Q68FF0	—	0.979	Q68FF0 →
Q6YTI2	—	0.979	Q6YTI2 →
Q8BMD7	—	0.979	Q8BMD7 →
Q9LR65	—	0.979	Q9LR65 →
Q6DFV7	—	0.979	Q6DFV7 →
Q62661	—	0.979	Q62661 →
Q8WML3	—	0.979	Q8WML3 →
Q94CU5	—	0.978	Q94CU5 →
CDC7	Cell division cycle 7-related protein kinase	0.978	landscape →
B2GUY1	—	0.978	B2GUY1 →
Q9SA22	—	0.978	Q9SA22 →